trending Market Intelligence /marketintelligence/en/news-insights/trending/JUn4F2mqWjNm-kbHjkKuPg2 content esgSubNav
In This List

HHS division, Cytori execute $13.4M contract option

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


HHS division, Cytori execute $13.4M contract option

The Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, signed a contract option valued at about $13.4 million with Cytori Therapeutics Inc.

The executed option will fund Cytori's clinical trial of Cytori Cell Therapy to develop it as a medical countermeasure for thermal burn injury.

According to the company, the contract option increases the authority's overall commitment to Cytori technology to about $34.6 million.

The original contract retains two as-yet unfunded options valued at up to $68 million. The first option is written to support a clinical trial that could potentially follow the present clinical trial on Cytori Cell Therapy and lead to its U.S. FDA approval as a treatment for thermal burn injury.

The second option addresses additional preclinical work targeting application in thermal burn and radiation injury.